Skip to main content

Posts

Showing posts with the label sarbecovirus

#SARS-CoV-2 #antibody #immunity across three #continents: the West #Africa, West #Indies, West #London Consortium

Abstract Background :  The experience of the COVID-19 pandemic has differed across continents. We hypothesized that regional differences in SARS-CoV-2 immunity might explain this observation. We therefore established the WWW Consortium in Ghana , W Africa; Jamaica , W Indies ; and W London . Here, we describe the extent to which antibody immunity differs between these geographic locations.  Methods :  The WWW Consortium harmonises across the HERITAGE (Accra, Ghana), WINDFall (Kingston, Jamaica) and Legacy (London, UK) studies, establishing sharing frameworks for samples , metadata, and data; related permissions and oversight; and associated physical and cloud infrastructure. With centralised testing, we performed serological assessments across all three locations at two snapshots in 2024 (April 1st - August 18th; August 19th - December 31st) using high-throughput live virus neutralization and anti-nucleocapsid IgG, including n=763 individuals.  Findings :  We fo...

#Coronavirus Disease Research #References (by AMEDEO, June 14 '25)

  Antiviral Res CHANG CW, Oswal N, Murugan M, Goldgirsh K, et al A novel cellular tool for screening human pan-coronavirus antivirals. Antiviral Res. 2025 Jun 10:106212. doi: 10.1016/j.antiviral.2025.106212. PubMed           Abstract available Clin Infect Dis LEE R, Kim N, Kim WB, Im KI, et al Effectiveness and safety of Autologous Virus-Specific T Cell Therapy for Persistent COVID-19 in People with Immunocompromise: A Clinical Trial Study. Clin Infect Dis. 2025 Jun 10:ciaf302. doi: 10.1093. PubMed           Abstract available SUDNIK P, Walsh EE, Branche AR, Islam M, et al Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized with RSV. Clin Infect Dis. 2025 Jun 12:ciaf310. doi: 10.1093. PubMed           Abstract available Int J Infect Dis WEE LE, Ho RWL, Lim JT, Chiew CJ, et al Long-term multi-systemic sequelae post-hospitalizat...

#Management and #outcomes of #children hospitalised with #COVID19 including Incidental and Nosocomial infections in #Australia 2020-2023: a national surveillance study

Highlights •  Acute COVID-19 usually causes mild illness even in young and immunosuppressed children •  Nosocomial SARS-CoV-2 infection is associated with more severe disease •  Concurrent serious bacterial infection is rare in children admitted with acute COVID-19. ABSTRACT Background Management and outcomes of children hospitalised with acute SARS-CoV-2 infection may differ throughout the pandemic or with admission type (clinical COVID-19, incidental COVID-19 or nosocomial infection). Objectives Describe the severity, management and outcomes of hospitalised children with acute SARS-CoV-2 infection in Australia across the first 4 years of the pandemic and compare between admission types, SARS-CoV-2 variants, age groups and immune status. Study design A multi-centre prospective cohort study of 6,009 children aged 0-16 years between January 2020 to June 2023. Results Most children (84.3%) did not receive respiratory support , 33.4% received antibiotics and 8% were admitted...

Long-term serial passaging of #SARS-CoV-2 reveals #signatures of convergent #evolution

ABSTRACT Understanding viral evolutionary dynamics is crucial to pandemic responses, prediction of virus adaptation over time , and virus surveillance for public health strategies. Whole-genome sequencing (WGS) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has enabled fine-grained studies of virus evolution in the human population . Serial passaging in vitro offers a complementary controlled environment to investigate the emergence and persistence of genetic variants that may confer selective advantage . In this study, nine virus lineages , including four “ variants of concern ” and three former “ variants under investigation ,” were sampled over ≥33 serial passages (range 33–100) in Vero E6 cells . WGS was used to examine virus evolutionary dynamics and identify key mutations with implications for fitness and/or transmissibility. Viruses accumulated mutations regularly during serial passaging. Many low-frequency variants were lost , but others became fixed, suggestin...

#Coronavirus Disease Research #References (by AMEDEO, June 7 '25)

  Ann Intern Med MARCUCCI M, Chan MTV, Painter TW, Efremov S, et al Effects of a Hypotension-Avoidance Versus a Hypertension-Avoidance Strategy on Neurocognitive Outcomes After Noncardiac Surgery. Ann Intern Med. 2025 Jun 3. doi: 10.7326/ANNALS-24-02841. PubMed           Abstract available GOLDMAN JM, Moyer DV Flying the Plane While Building It: Lessons From the COVID-19 Pandemic. Ann Intern Med. 2025 Jun 3. doi: 10.7326/ANNALS-25-02436. PubMed          Antiviral Res MALUNE P, Esposito F, Tramontano E Unveiling SARS-CoV-2's heart: role, structure and inhibition of SARS-CoV-2 RNA-dependent RNA polymerase. Antiviral Res. 2025 Jun 3:106208. doi: 10.1016/j.antiviral.2025.106208. PubMed           Abstract available BMJ MURPHY F Covid-19: New variant spreading across Asia is found in UK. BMJ. 2025;389:r1161. PubMed          LOOI MK Trump wa...

#Virological characteristics of the #SARS-CoV-2 #NB181 #variant

{Excerpt} After the spread of SARS-CoV-2 JN.1, its subvariants, such as KP.3 (JN.1.11.1.3)1 and KP.3.1.1 (JN.1.11.1.3.1.1),2 and XEC (a recombinant lineage of two JN.1 subvariants),3 emerged and rapidly spread globally. Subsequently, LP.8.1 (JN.1.11.1.1.1.3.8.1),4 a descendant lineage of KP.1.1.3 (JN.1.11.1.1.1.3), accounts for approximately 30% of all global infections as of April, 2025 , as per data from Nextstrain. Thereafter, NB.1.8.1 (XDV.1.5.1.1.8.1), a descendant lineage of XDV , has started to spread worldwide. XDV is a recombinant lineage of XDE (a recombinant lineage of GW.5.1 [XBB.1.19.1.5.1] and FL.13.4 [XBB.1.9.1.13.4]) and JN.1. NB.1.8.1 has acquired seven spike substitutions and 23 non-spike substitutions compared with JN.1 (appendix pp 15–16). Compared with the XEC spike protein, the NB.1.8.1 spike bears four substitutions : G184S, K478I, A435S, and L1104V (appendix pp 15–16). We estimated the relative effective reproduction number (Re) of NB.1.8.1 using a Bayesian mult...

#Antigenic and #virological characteristics of #SARS-CoV-2 #variants BA.3.2, #XFG, and #NB181

{Excerpt} The SARS-CoV-2 saltation variant BA.3.2 , harbouring over 50 mutations relative to its ancestral BA.3 lineage , has recently drawn global attention (figure A). Notably, BA.3.2 exhibits 44 mutations distinct from the currently dominant LP.8.1/LP.8.1.1 variant (appendix p 4), raising speculation about its potential to drive an outbreak similar to BA.2.86 /JN.1, particularly following its first detection outside South Africa in the Netherlands on April 2, 2025.1–5 A critical evaluation of its antigenic profile and infectivity is essential to establish its likelihood of prevailing. (...) Source: The Lancet Infectious Diseases,  https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00308-1/fulltext?rss=yes ____

#SARS-CoV-2 infection #enhancement by #amphotericin B: implications for disease management

ABSTRACT Severe coronavirus disease 2019 (COVID-19) patients who require hospitalization are at high risk of invasive pulmonary mucormycosis . Amphotericin B (AmB), which is the first-line therapy for invasive pulmonary mucormycosis, has been shown to promote or inhibit replication of a spectrum of viruses. In this study, we first predicted that AmB and nystatin had strong interactions with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins using in silico screening, indicative of drugs with potential therapeutic activity against this virus. Subsequently, we investigated the impact of AmB, nystatin, natamycin, fluconazole, and caspofungin on SARS-CoV-2 infection and replication in vitro. Results showed that AmB and nystatin actually increased SARS-CoV-2 replication in Vero E6, Calu-3, and Huh7 cells . At optimal concentrations, AmB and nystatin increase SARS-CoV-2 replication by up to 100- and 10-fold in Vero E6 and Calu-3 cells, respectively. The other antifungals t...

Persistence of #SARS-CoV-2 #Alpha #Variant in White-Tailed #Deer, #Ohio, USA

Abstract Free-ranging white-tailed deer (WTD) are highly susceptible to the SARS-CoV-2 virus . Through an opportunistic sampling of WTD in northeast Ohio, USA , during January–March 2023 , we identified 6 SARS-CoV-2 lineages from 36 sequences using the pangolin lineages tool, including the B.1.1.7 lineage (Alpha variant) and BQ.1.1, BQ.1.1.63, BQ.1.1.67, BQ.1.23, and XBB.1.5.35 lineages ( Omicron variant ). The Alpha variant, introduced by a single human-to-deer transmission event , was detected in 5 WTD in January 2023, more than 1 year after the most recent detection of the Alpha variant in humans in Ohio (August 2021). A genetically similar B.1.1.7 lineage virus from WTD in a nearby county in Pennsylvania was positioned with our Ohio deer transmission cluster, suggesting deer-to-deer transmission . The persistence of the Alpha variant in WTD in Ohio warrants continued surveillance to monitor if WTD can become a reservoir for displaced SARS-CoV-2 variants. Source: US Centers for Dise...

#Coronavirus Disease Research #References (by AMEDEO, May 31 '25)

  Am J Respir Crit Care Med KRISHNAN JA, Cao B, Chotirmall SH, Ely EW, et al Using the 2024 NASEM Definition of Long COVID: Implications for Pulmonary and Critical Care Medicine. Am J Respir Crit Care Med. 2025. PubMed          BMJ IBRAHIM S, Siemieniuk RAC, Oliveros MJ, Islam N, et al Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis. BMJ. 2025;389:e081165. PubMed           Abstract available BOSAEED M, Alraddadi BM Navigating the complexities of mild and moderate covid-19 treatment. BMJ. 2025;389:r1016. PubMed          TANNE JH US no longer recommends covid-19 vaccinations for pregnant women or children. BMJ. 2025;389:r1104. PubMed          O'DOWD A, Iacobucci G Covid-19: Early call to test healthcare staff was ignored, inquiry hears. BMJ. 2025;389:r1092. PubMed       ...

#COVID19 - Global #Situation (#WHO, D.O.N., June 28 '25)

  Situation at a glance Since mid-February 2025, according to data available from sentinel sites, global SARS-CoV-2 activity has been increasing, with the test positivity rate reaching 11%, levels that have not been observed since July 2024.  This rise is primarily observed in countries in the Eastern Mediterranean, South-East Asia, and Western Pacific regions .  Since early 2025 , global SARS-CoV-2 variant trends have slightly shifted. Circulation of LP.8.1 has been declining, and reporting of NB.1.8.1, a Variant Under Monitoring (VUM), is increasing , reaching 10.7% of global sequences reported as of mid-May.  Recent increases in SARS-CoV-2 activity are broadly consistent with levels observed during the same period last year, however, there still lacks a clear seasonality in SARS-CoV-2 circulation, and surveillance is limited.  Continued monitoring is essential . WHO advises all Member States to continue applying a risk-based, integrated approach to managing C...

#Coronavirus Disease Research #References (by AMEDEO, May 24 '25)

  AJR Am J Roentgenol SCHMITT JE, Smerconish S Beyond the AJR: Demystifying COVID-19-Related Brain Fog With Perfusion MRI. AJR Am J Roentgenol. 2025 May 21. doi: 10.2214/AJR.25.32998. PubMed          Br J Anaesth WELLER JM, Long J, Moore M, Henderson K, et al Effects of a national team training intervention for operating theatre teams on patient and staff outcomes: a stepped-wedge cluster-randomised trial and mixed-methods study. Br J Anaesth. 2025 May 16:S0007-0912(25)00230-2. doi: 10.1016/j.bja.2025. PubMed           Abstract available Clin Infect Dis NADIG N, Bhimraj A, Cawcutt K, Chiotos K, et al 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab. Clin Infect Dis. 2025 May 22:ciaf235. doi: 10.1093. PubMed           Abstract available Int J Infect Dis HUANG Q, Kang L, Wei X, ...

Endemic #coronavirus #infection is associated with #SARS-CoV-2 Fc receptor-binding #antibodies

ABSTRACT Recent documented infection with an endemic coronavirus (eCoV) is associated with less severe coronavirus disease 2019 (COVID-19), yet the immune mechanism behind this protection has not been fully explored. We measured both antibody and T-cell responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in SARS-CoV-2- naïve individuals , classified into two groups: those with or without presumed recent eCoV infections . There was no difference in neutralizing antibodies and T-cell responses against SARS-CoV-2 antigens between the two groups. SARS-CoV-2-naïve individuals with recent presumed eCoV infection, however, had higher and significantly correlated levels of Fc receptor (FcR)-binding antibodies against eCoV spikes (S) and SARS-CoV-2 S2. Recent eCoV infection boosts cross-reactive antibodies that can mediate Fc effector functions, and this may play a role in the observed heterotypic immune protection against severe COVID-19. IMPORTANCE With the recent e...

#Evolution of #Antiviral Drug #Resistance in #SARS-CoV-2

Abstract The COVID-19 pandemic has had a significant impact and continues to alarm the entire world due to the rapid emergence of new variants , even after mass vaccinations . There is still an urgent need for new antivirals or strategies to combat the SARS-CoV-2 infections; however, we have success stories with nirmatrelvir . Drug repurposing and drug discovery may lead to a successful SARS-CoV-2 antiviral; however, rapid drug use may cause unexpected mutations and antiviral drug resistance. Conversely, novel variants of the SARS-CoV-2 can diminish the neutralizing efficacy of vaccines, thereby enhancing viral fitness and increasing the likelihood of drug resistance emergence. Additionally, the disposal of antivirals in wastewater also contributes to drug resistance. Overall, the present review summarizes the strategies and mechanisms involved in the development of drug resistance in SARS-CoV-2. Understanding the mechanism of antiviral resistance is crucial to mitigate the significant...

#Coronavirus Disease Research #References (by AMEDEO, May 17 '25)

  Am J Respir Crit Care Med EDDY RL, Sin DD Loss of Lung Function Led to Loss of Life During the COVID-19 Pandemic. Am J Respir Crit Care Med. 2025. PubMed          Ann Intern Med JACOBS JW, Booth GS, Lewis-Newby M, Saifee NH, et al Medical, Societal, and Ethical Considerations for Directed Blood Donation in 2025. Ann Intern Med. 2025 May 13. doi: 10.7326/ANNALS-25-00815. PubMed           Abstract available BMJ WISE J Covid-19: Attitudes shifted after politicians broke rules, report says. BMJ. 2025;389:r960. PubMed          Br J Anaesth COPLEY S, Carty S, Brown M, Mishra S, et al Bridging the GAP: a critical analysis of pain management services in the United Kingdom. Br J Anaesth. 2025;134:1597-1602. PubMed           Abstract available Clin Infect Dis HAWKINS KL, Dandachi D, Verzani Z, Brannock MD, et al HIV Infection and Long COVID: ...